HelpAcademyLoginJoin us as a Member

KYV-101

Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yetListed from FDA or ClinicalTrials.gov records; an editor has not checked it yet.

Kyverna Therapeutics, Inc. KYTX · Generalized Myasthenia Gravis; Myasthenia Gravis

Sign in to save KYV-101 to a watchlist Sign in to set an alert for KYV-101

Key figures

  • Next catalyst

    None scheduled

    Only dates with a source are listed

  • Phase

    Phase 2/3

    Not recorded

  • Linked trials

    1

    From ClinicalTrials.gov

  • Latest FDA action

    None on record

    From Drugs@FDA

Recalls, shortages, patents and EU status at a glance

Key information

Sponsor
Kyverna Therapeutics, Inc. KYTX Source: Company record for Kyverna Therapeutics, Inc. (opens in a new tab)
Indications
Generalized Myasthenia Gravis; Myasthenia Gravis Source: Conditions from ClinicalTrials.gov (opens in a new tab)
Designations
None recorded
Next catalyst
None scheduled

Development timeline

  1. Preclinical Completed
  2. Phase 1 Completed
  3. Phase 2 Current stageFirst trial start 28 Aug 20241 linked trial
  4. Phase 3 Current stageFirst trial start 28 Aug 20241 linked trial
  5. Filed Not yet
  6. Approved Not yet

Overview

Mechanism
Not recorded
Route
Not recorded
Modality
Not recorded
Specialties
Not recorded

Overview text is written by HealthTrade editors.

Key dates

No catalysts yet. Editors add each date together with its source.

FDA designations

No FDA designations are on record for KYV-101. Editors add each one with its source.

Filed application

No filed application is on record for KYV-101. Approvals are listed under FDA actions.

FDA advisory committees

No FDA advisory committee meetings are on record for KYV-101.

Clinical trials

Trials linked to KYV-101
TrialTitlePhaseStatusEnrollmentPrimary completionResults posted
NCT06193889ClinicalTrials.gov record for NCT06193889 (opens in a new tab)KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisPhase 2/3Recruiting66 (estimated)Sep 2027 (estimated) No

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.

Trial quality

About CT-VCA

Loading trial quality…

FDA actions

No FDA approvals on record for this drug.

FDA recalls load here.

FDA drug shortages load here.

Orange Book patents load here.

FAERS adverse event counts load here.

Papers and preprints load here.

Community discussion loads here.

EU status (EMA)

EMA's medicines data lists no human medicine with the same active substance as KYV-101.

Source: European Medicines Agency (EMA), medicines data download.

Related news

No recent headlines mention this drug.

Sources

Record updated .

Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.